|

Ramucirumab Clinical Trials

19 actively recruiting trials across 14 locations

Also known as: Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, CYRAMZA®, Cyramza, IMC 1121B, IMC-1121B, IMC1121B, LY 3009806, LY-3009806, LY3009806, Monoclonal Antibody HGS-ETR2

Birmingham, Alabama2 trials

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Childrens Hospital of Alabama

Phase 2
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

University of Alabama at Birmingham Cancer Center

Phase 2

Daphne, Alabama2 trials

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

Phase 2/3
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

Phase 2

Anchorage, Alaska2 trials

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Katmai Oncology Group

Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Anchorage Associates in Radiation Medicine

Phase 2

Duarte, California2 trials

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

City of Hope

Phase 2
Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

City of Hope Medical Center

Phase 1

Other1 trial

AB122 Platform Study
Phase 1

Phoenix, Arizona1 trial

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site

Phase 1/2

Tucson, Arizona1 trial

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927)

Phase 1/2

Little Rock, Arkansas1 trial

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Baptist Health Medical Center - Little Rock

Phase 2/3

Los Angeles, California1 trial

Volrustomig Priming Regimens Exploratory Phase II Platform Study

Research Site

Phase 2

Orange, California1 trial

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

University of California Irvine Medical Center

Phase 1

Santa Monica, California1 trial

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Research Site

Phase 2

Rochester, Minnesota1 trial

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Mayo Clinic- Minnesota

Phase 2

Basking Ridge, New Jersey1 trial

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Middletown, New Jersey1 trial

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Phase 1/2

Philadelphia, Pennsylvania1 trial

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Abramson Cancer Center of the University of Pennsylvania

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.